Purpose

- Prequalified Vaccine Annual Product Report (PQVAR) is a part of the **continued assessment** of the **acceptability** of vaccines that are purchased by the United Nations procurement agencies.

- PQVAR shall be also used as a tool for risk based reassessment of prequalified vaccines.
For the manufacturer

- This is one of the obligations of a manufacturer after prequalification is granted to a vaccine as per revised PQ procedure (WHO/BS/10.2155 or TRS 978 - Annex 6)
Guidance Documents

- The minimum information that is submitted to the PQ Secretariat as part of the PQVAR is described in section 8 (Annual Reporting) of “Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies” which is included in WHO/BS/10.2155 and is the annex 6 of WHO TRS 978
Requirements

A. VARIATIONS
B. STABILITY TEST RESULTS
C. PRODUCTION & DISTRIBUTION DATA
D. REGULATORY INSPECTIONS
E. POST PQ COMMITMENTS
F. PERIODIC SAFETY UPDATE REPORT (PSUR)
Monitoring performance of PQed vaccines

- Targeted testing (contracted labs worldwide). Once a year testing of samples of lots shipped to the field to ensure continuing compliance with specifications

- Monitoring and resolution of complaints and reports of AEFIs (with collaboration of the responsible NRA)

- Reassessments frequency defined on risk analysis based
Deadline for submission of PQVAR

- 3 deadlines for submission: 31 January, 31 May and 30 September

- Submission of the **first annual report** should be the **first submission deadline one year after** the date of prequalification, with **subsequent** submissions each year on the **same date**

- **Examples:**
  1. PQ date on 15 July 2014:
     - First PQVAR submission date: next deadline after the PQ date + 1 year (15 July 2014 + 1 = 15 July 2015) which is 30 Sep 2015
     - Next PQVARs after first PQVAR: 30 Sep 16, 30 Sep 17,....
  2. PQ date on 22 Oct 2014:
     - First PQVAR submission date: next deadline after the PQ date + 1 year (22 Oct 2014 + 1 = 22 Oct 2015) which is 31 Jan 2016
     - Next PQVARs after first PQVAR: 31 Jan 2017, 31 Jan 2018,....
Number of Manufacturers, Country & Type of Vaccine and PQVAR in 2014 (received online)

Expected PQVAR: 141
Common gaps and challenges 1/3

- The focal point is not updated
- Responsible officer for specific vaccine is not updated
- Submission not on time and offline
- Product (invented and non-proprietary name) Not provided
- Brand Name not provided
- Manufacturing Country Name not provided
Common gaps and challenges 2/3

- PQVAR Report number not provided.

- Stability:
  - stability Program not provided
  - lack of trend analysis for testing stability data
  - in case of a vaccine shelf life extension, the real time stability testing protocol should be covered the new proposed shelf life.

- Variation:
  - table not provided
  - No reference to major variation (s) which must be submitted before any implementation

- Data not adequate
Common gaps and challenges 3/3

- Proof of acceptance from responsible NRA not provided.
- Status of PQ commitments not provided
- GMP inspection
  - brief outcomes not provided properly (only a list of inspections)
  - results such as satisfactory/not satisfactory/satisfactory with minor observations/recommendation etc… are expected
- It seems to be document generated without QMS control.
Risk based reassessment

**Parameters:**
- Lots rejected, released.
- Number (and type) of variation
- Interruption of production (reasons)
- Complaints/AEFIs
- WHO experience: Number of years PQed, number of PQed products, last WHO satisfactory audit, suspensions/warning letters
- Volume of supply and number of other suppliers
- NRAs: time of assessment as functional, agreements signed, responsiveness, oversight
Introduction to the PQVAR module

Type or paste the following link in address tab of your browser to reach the PQVAR module.

https://extranet.who.int/gavi/PQ_MAFRep/Login.aspx

Login screen will appear
Login Screen

- **Common Login Screen**: both for Manufacturer and WHO.

- **Individual Login**: (Dropdown for WHO WIMS account) and Password.

- On the login screen total number of reports submitted highlighted.
Login Screen
After login Module for PQVAR Submission, Screening and Evaluation Screen will appear

From the filter report section either select the Manufacture or the vaccine.

The whole page give the information about submitted PQVAR viz

- Vaccine
- Manufacturer
- NRA
- Submitted Date
- Screened Date
- Clinically Evaluated
- Evaluated
- Information Required
- Closed
To Access the information

- Either select the vaccine or of manufacture and hit the filter button
- Or directly click on the vaccine name to access the information.
- New page Vaccine Annual Report Cover will appear after clicking on the particular vaccine.
Vaccine Annual Report Cover

Annual Cover Report Cover page contains

- Cover Page
- Content
- Attachments
- Performance/Manufacturing Information
- Preview Risk Reassessment Report
- Preview PQVAR
<table>
<thead>
<tr>
<th>Recapitulation</th>
<th>Manufacturer:, Vaccine, NRA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report Identification</td>
<td>Manufacturer Reference:, WHO Reference:</td>
</tr>
<tr>
<td>Manufacturer Information</td>
<td>Name, Address, Telephone, Facsimile, e-mail:</td>
</tr>
<tr>
<td>Responsible Officer</td>
<td>Officer Responsible, Contact Information</td>
</tr>
<tr>
<td>NRA Contacts for the Country of Manufacturer</td>
<td>NRA, Principal Contact, Contact Information</td>
</tr>
<tr>
<td>Vaccine Type: Brand Name Vaccine Details:</td>
<td>Vaccine Type, Vaccine Type Remarks, Brand Name, Prequalification Status, Current Prequalification Date, Prequalification Status Remarks and Bulk Supplier</td>
</tr>
<tr>
<td>Additional information</td>
<td>Manufacturer Remarks, WHO Remarks</td>
</tr>
</tbody>
</table>
Vaccine Annual Report Content

After Clicking the Content Tab  Content Page opened

Recapitulation
Manufacturer: Serum Institute of India Limited - India  
Vaccine: Hepatitis B: Hepatitis B Vaccine (DNA) (Adult)  
NRA: India: Central Drugs Standard Control Organization

A. Variations Summary - Not more than 1000 words
- Total no. of changes: 15 nos.
- Changes related to Drug substance (HBsAg): No change since the changes listed in last PQVAR submitted in October 2012 as a part of DTP+Hib+Rb vaccine.
- Changes related to Drug Product (Hepatitis B Vaccine): Serum Institute of India Limited- India

<table>
<thead>
<tr>
<th>P</th>
<th>NA</th>
<th>Manufacturer Comments</th>
<th>Screening Comments</th>
<th>Evaluation Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Angiologos and limit of kph is changed from 0.25 EU/mL to 1 EU/mL for bacterial endotoxin test by HTA are relaxed. Rationales for changed limit are provided.</td>
<td>There have been several changes that needed to be assessed by WHO before implementation that were submitted to WHO. Some UN tender were not shortlisted.</td>
</tr>
</tbody>
</table>

B. Stability Programs Test Results Summary - Not more than 1000 words
- Ongoing stability data of Drug substance (HBsAg): 06 batches: stability study of lot No. 084-817, 084-818, 084-311 and 085K00106 is ongoing and are found to be stable up to 45, 45, 40 and 9 months respectively.
Vaccine Annual Report Content conti...

After Clicking the Content Tab, Content Page will be opened.

- Page contains the summary of all the 5 mandates viz:
  - Variations
  - Stability Programs Test Results
  - Production and Distribution Summary
  - Regulatory Inspections Summary
  - Post PQ Commitments Summary
  - Periodic Safety Update Report Summary

- Manufacturer comments
- Screening Comments
- Evaluation Comments
  - Outcome Screening
  - Outcome Evaluation
  - Outcome Of the Evaluation (CI)
  - Final Decision/Actions:
  - Evaluation Closed

World Health Organization
• Manufacturer will provide the summary of all the 5 mandate viz
  ✓ Variations
  ✓ Stability Programs Test Results
  ✓ Production and Distribution Summary
  ✓ Regulatory Inspections Summary
  ✓ Post PQ Commitments Summary
  ✓ Periodic Safety Update Report Summary
Along with their comments
Screener will evaluate the submitted data and provide comments in screener comments column.
Variations other than minor

- A module similar to PQVAR for variations which need to be approved by WHO before implementation (major), is in development

- Manufacturers will be able to submit online major variation and immediate notification

- Variation document under finalization.
Variations 1/2

- Variations that may impact on the quality, safety and efficacy of the vaccine should be approved by the NRA and reviewed by WHO before implementation.

- Supply through the UN system only after confirmation by WHO

- UN procuring agencies will be informed by WHO (e.g. labels, inserts, additional presentations)

- WHO webpage may be updated
Manufacturer should submit:

- Justification of the variation
- Documentation supporting the variation
- Timelines for implementation
- Approval by the National Regulatory Authority

Additional information may be requested by WHO
THANK YOU